Abstract
Background and objectivesThe 24-week open-label Phase 3 KIWI study demonstrated that the pharmacokinetics and safety of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
